

## Publications And Research

1. Vishal Gupta et al, Does Sacubitril/Valsartan Combination Therapy Provide Additional Renal Benefits In Type 2 Diabetes Mellitus, Receiving Canagliflozin? ADA, Virtual Meeting, 2021 (P-784) ([https://diabetes.diabetesjournals.org/content/70/Supplement\\_1/784-P](https://diabetes.diabetesjournals.org/content/70/Supplement_1/784-P))
2. Vishal Gupta et al: A Case Series of Hypopituitarism Presenting As Nocturnal Hypoglycaemia In Patients With Type 2 Diabetes Mellitus, Poster, ECE 2020 Sept (virtual meeting) (<https://www.endocrine-abstracts.org/ea/0070/ea0070ep305>)
3. Vishal Gupta et al: To compare the efficiency of canagliflozin (C1) 100mg Vs canagliflozin (C3) 300mg on vascular protection (hs-CRP), ADA, Chicago, 2020 (Pub-2219) ([https://diabetes.diabetesjournals.org/content/69/Supplement\\_1/2219-PUB](https://diabetes.diabetesjournals.org/content/69/Supplement_1/2219-PUB))
4. Vishal Gupta et al: Effect of sacubitril/Valsartan combination therapy in type 2 diabetes mellitus patients with elevated NT-ProBNP & preserved ejection fraction ADA, Chicago, Virtual meeting, 2020 (P-1069) ([https://diabetes.diabetesjournals.org/content/69/Supplement\\_1/1069-P](https://diabetes.diabetesjournals.org/content/69/Supplement_1/1069-P))
5. Vishal Gupta et al; "To evaluate the relationship between HSCRP and NT-proBNP in 200 type 2 diabetes patients optimised for conventional cardiovascular and renal risk factors at the end of 2 years, Submission-Number: A-19-346-EASD, Barcelona Sept 2019 (<https://www.easd.org/virtualmeeting/home.html#!resources/to-evaluate-the-relationship-between-hscrp-and-nt-probnp-in-200-type-2-diabetes-patients-optimised-for-conventional-cardiovascular-and-renal-risk-factors-at-the-end-of-2-years-b69358fa-782f-4b5f-b5bc-f5514587d5e7>)
6. Dr. Vishal Gupta et al, Canagliflozin may Offer Vascular and Renal Protection in Patients with Type 2 Diabetes Mellitus- An Indian Perspective. Indian Journal of Cardiology. Photon, 2019, 112, 145- 165 (<https://sites.google.com/site/internationalindexing/canagliflozin-may-offer-vascular-and-renal-protection-in-patients-with-type-2-diabetes-mellitus--an-indian-perspective-by-dr-vishal-gupta-dr-vaishali-teli-prof-dr-ataf-patel>)
7. Vishal Gupta et al; Comparison of Cardiovascular (NT-ProBNP) and Renal Biomarkers in 280 T2DM Patients with Microalbuminuria vs. Normoalbuminuria, ADA, June 2019, Diabetes P-4962 (Pub) ([https://diabetes.diabetesjournals.org/content/68/Supplement\\_1/2229-PUB?utm\\_source=TrendMD&utm\\_medium=cpc&utm\\_campaign=Diabetes\\_TrendMD\\_0](https://diabetes.diabetesjournals.org/content/68/Supplement_1/2229-PUB?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0))

8. Vishal Gupta et al; Despite Optimal Use of Angiotensin Receptor Blockers There Exists Substantial Cardiovascular Risk as Suggested by Elevated NT-ProBNP in 259 T2DM Patients, ADA, June 2019, Diabetes, 2210 (Pub) ([https://diabetes.diabetesjournals.org/content/68/Supplement\\_1/2210-PUB?utm\\_source=TrendMD&utm\\_medium=cpc&utm\\_campaign=Diabetes\\_TrendMD\\_0](https://diabetes.diabetesjournals.org/content/68/Supplement_1/2210-PUB?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0))
9. Vishal Gupta et al; Effect of High Dose vs. Conventional Dose Angiotensin Receptor Blockers in 175 T2DM with Microalbuminuria on CV (NT-ProBNP) and Renal Biomarkers , ADA, June 2019, 1125-P (Poster) ([https://diabetes.diabetesjournals.org/content/68/Supplement\\_1/1125-P?utm\\_source=TrendMD&utm\\_medium=cpc&utm\\_campaign=Diabetes\\_TrendMD\\_0](https://diabetes.diabetesjournals.org/content/68/Supplement_1/1125-P?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0))
10. Vishal Gupta et al; , Comparison of Telmisartan vs. Valsartan on Cardiovascular and Renal Biomarkers in 84 Patients with T2DM with Microalbuminuria, ADA, June 2019, 1126-P (poster) ([https://diabetes.diabetesjournals.org/content/68/Supplement\\_1/1126-P?utm\\_source=TrendMD&utm\\_medium=cpc&utm\\_campaign=Diabetes\\_TrendMD\\_0](https://diabetes.diabetesjournals.org/content/68/Supplement_1/1126-P?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0))
11. Vishal Gupta et al; N-Terminal pro-B-type Natriuretic Peptide (NT-pro BNP) is a Strong Predictor of Cardiovascular Risk in Patients with Type 2 Diabetes Optimised for Conventional Cardiovascular and Renal Risk Factor, And Its Relationship With Highly Sensitive C-Reactive Protein (Hs-CRP) At The End Of 2 Years, Indian Journal of Cardiology Photon, 2019, 112, 130-144 (<https://sites.google.com/site/internationalindexing/n-terminal-pro-b-type-natriuretic-peptide-nt-pro-bnp-is-a-strong-predictor-of-cardiovascular-risk-in-patients-with-type-2-diabetes-optimized-for-conventional-cardiovascular-and-renal-risk-factor-and-its-relationship-with-highly-sensitive-creactive-protein-hs-crp-at-the-end-of-2-years>)
12. Vishal Gupta et al; An Observational Study To Evaluate Change In Dose Requirement Of Standard Glucose Lowering, Lipid Lowering And Anti-hypertensive Therapy Treated With SGLT2-inhibitor (Canagliflozin) Over One Year, In Fifty T2DM Patients, ADA, June 2018, P-1165, Orlando. ([https://diabetes.diabetesjournals.org/content/67/Supplement\\_1/1165-P](https://diabetes.diabetesjournals.org/content/67/Supplement_1/1165-P))
13. Vishal Gupta et al; To Evaluate Patient Characteristics In Those With Elevated NT-proBNP In Type 2DM patients Optimisation For Conventional CV Risk Factors On Standard Care For 2 Years, ADA, June 2018, P-1516, Orlando ([https://diabetes.diabetesjournals.org/content/67/Supplement\\_1/1516-P](https://diabetes.diabetesjournals.org/content/67/Supplement_1/1516-P))
14. Vishal Gupta et al; The Role Of NT-proBNP As A Biomarker In Evaluating Residual Cardiovascular Risk In 200 Type 2 DM Patients Optimised For Conventional CV Risk

Marker Over 2 years, ADA, June 2018, P- 1513, Orlando ([https://diabetes.diabetesjournals.org/content/67/Supplement\\_1/1513-P](https://diabetes.diabetesjournals.org/content/67/Supplement_1/1513-P))

15. Vishal Gupta; Michael Willis et al ; Long-term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India, Value in Health Regional Issues, Volume 18 , 65 - 73 (<https://pubmed.ncbi.nlm.nih.gov/30502662/>)
16. Gupta V, et al. Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal. Indian J Endocr Metab 2017;21:909-18. (<https://pubmed.ncbi.nlm.nih.gov/29285458/>)
17. Gupta V, Teli V, Subgroup analysis to evaluate effects of baseline characteristics on markers of renal and cardiovascular risk in type 2 diabetes patients treated with SGLT2 inhibitor (canagliflozin), published abstract (P2418-PUB) at American Diabetes Association 2017, San Diego, USA
18. Teli V, Gupta V; A real life prospective study to evaluate effect of sodium-glucose co-transporter-2 inhibitor (canagliflozin) therapy on cardiovascular and renal markers in patients with type 2 diabetes mellitus, Poster session (P1204) at American Diabetes association 2017, San Diego, USA
19. Gupta V et al; An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes, J Med Econ. 2015 Apr;18(4):263-72 (<https://pubmed.ncbi.nlm.nih.gov/25426701/>)
20. Gupta V et al; predictive and explanatory factors of change in health related quality of life after starting insulin analogs, ADA abstract, June 2015
21. Gupta V et al; Pituitary apoplexy presenting as myocardial infarction. Indian J Endocr Metab 2014; 18:232-3 (<https://pubmed.ncbi.nlm.nih.gov/24741524/>)
22. Asrul Akmal Shafie, Vishal Gupta et al; An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes; diabetes research and clinical practice , 2014, 106, 319-327 (<https://pubmed.ncbi.nlm.nih.gov/25305133/>)
23. Gupta V. Normocalcemic primary hyperparathyroidism in a patient with severe osteoporosis receiving teriparatide. Indian J Endocr Metab 2013;17:336-8 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683218/>)
24. Cheng ML, Gupta V. Premenopausal osteoporosis. Indian J Endocr Metab 2013;17:240-4 (<https://pubmed.ncbi.nlm.nih.gov/23776895/>)

25. Gupta V; Simultaneous presentation of giant pheochromocytoma, primary hyperparathyroidism, and mixed-medullary-papillary thyroid cancer in MEN 2A. Indian J Endocr Metab, 2013;17:751-5. (<https://pubmed.ncbi.nlm.nih.gov/23961501/>)
26. Vishal Gupta; "GLP-1 analogues - a review"; Indian J Endocrinol Metab. 2013 May-Jun; 17(3): 413-421. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712370/>)
27. Talwalkar P G, Gupta V, et al; Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Mumbai cohort of the A 1 chief study. Indian J Endocr Metab, 2013, S2:516-20. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872902/>)
28. Kalra S, Gupta V. The diversity of diabetes. In: Bajaj S, ed. ESI Manual of Clinical Endocrinology. Hyderabad, Endocrine Society of India, 2012. pp 3-5.
29. Gupta V, Lee M, Growth hormone in chronic renal disease; Indian J Endocr Metab; 2012;16:195-203 (<https://pubmed.ncbi.nlm.nih.gov/22470855/>)
30. Gupta V. Vitamin D: Extra-skeletal effects. J Med Nutr Nutraceut 2012;1:17-26 (<https://www.jmnn.org/article.asp?issn=2278-1870;year=2012;volume=1;issue=1;spage=17;epage=26;aualast=Gupta>)
31. Gupta V, Pleiotropic effects of incretins. Indian J Endocr Metab 2012;16:47-56 (<https://pubmed.ncbi.nlm.nih.gov/22701844/>)
32. Gupta V, Shah MA, Shah SK, Shah JM. Osteoanabolics. Indian J Endocr Metab 2012;16:349-57 (<https://www.ijem.in/article.asp?issn=2230-8210;year=2012;volume=16;issue=3;spage=349;epage=357;aualast=Gupta;type=0>)
33. Cheng ML, Gupta V. Teriparatide - Indications beyond osteoporosis. Indian J Endocr Metab 2012;16:343-8 (<https://pubmed.ncbi.nlm.nih.gov/22629497/>)
34. Gupta V, Patil S, Shah D. Primary hyperparathyroidism associated with vitamin D toxicity in a patient with severe osteoporosis receiving teriparatide. Indian J Endocr Metab 2012;16:863-4 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475930/>)
35. Gupta V; Block and replace therapy using propylthiouracil and levothyroxine for Graves' disease during pregnancy, Indian J Endocrinol Metab. 2012 Jul-Aug; 16(4): 660-662. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401781/>)
36. Vishal Gupta et al, "Idiopathic Granulomatous Hypophysitis Presenting As Panhypopituitarism", The Endocrinologist, Vol 20(3), May/June 2010, pp 102-104
37. Vishal Gupta et al ; "Acromegaly Associated With Symptomatic Rathke's Cyst", Indian Journal of Endocrinology and Metabolism; April-Jun 2011, Vol 15, Issue 2. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125006/>)

38. Vishal Gupta et al, "Central Hypothyroidism - A Review", Indian Journal of Endocrinology and Metabolism, 2011, 15, Issue 6 [p. 99-106] (<https://pubmed.ncbi.nlm.nih.gov/2196662/>)
39. Vishal Gupta "Adult Growth Hormone Deficiency - A Review", Indian Journal of Endocrinology and Metabolism; 2011, 15, Issue:7 [p197-202] (<https://pubmed.ncbi.nlm.nih.gov/22029024/>)
40. Vishal Gupta et al; "Choosing A Gliptin", Indian Journal Of Endocrinology and Metabolism; 2011; 15; Issue : 4, [p298-308] (<https://pubmed.ncbi.nlm.nih.gov/22029001/>)
41. Vishal Gupta "Mineralocorticoid Hypertension - A Review", Indian J Endocr Metab; 2011; 15 ; Issue : 8; Page : 298- 302. (<https://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=8;spage=298;epage=312;aulast=Gupta>)
42. Vishal Gupta et al, "Parathyroid Storm Secondary To Parathyroid Adenoma Presenting With Necrotizing Pancreatitis", The Endocrinologist, Jan/Feb 2009 Volume 19 (1)
43. Gestational Diabetes - poster presentation Diabetic Medicine, P 305 Supplement 15, 2008-05-02

#### 44. Book chapters

- Editor in Chief for textbook titled: "Type 2 diabetes and beyond", Jaypee Brother Publishing Company, Published March 2021. (<http://www.jpmedpub.com/bookdetails.aspx?CatID=37&OBookID=3213>)

#### Author of the following chapters/sections:

- A. Gupta V; "From hyperglycaemia, to defining type 2 diabetes mellitus"; ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 1-16
- B. Gupta V; "Does it boil down to insulin resistance versus beta cell failure, Focus on Pathophysiology and Co-relation to therapeutics", ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 17-120
- C. Gupta V; "Beyond Diabetic dyslipidemia", ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 121-147
- D. Gupta V; "Unmet need in cardiovascular mortality Va- Hypertension, Vb - coronary heart disease, Vc - heart failure, Vd - stroke; ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 161-245
- E. Gupta V; "The reality behind assessing renal function" ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 246-284.
- F. Gupta V; "Diabetes and risk to cancer" ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 285-308

- G. Kapadia A, Gupta V; “Autoimmune associations with type 2 diabetes mellitus”, ed: Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 309-340
- H. Gupta V; “Type 2 Diabetes mellitus, Immunity and infection”, First Edition; Jaypee publishing house, 2021, Page 341-382
- I. Gupta K, Gupta V; Role of diet, does it matter?”, First Edition; Jaypee publishing house, 2021, Page 383-406
45. Gupta V; GLP-1 analogues and Insulin Combination, Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house, 2013, p50-57
- A. Gupta V; Pleiotropic effects of incretins; cardiovascular effects, Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house, 2013, p103
- B. Gupta V; Pleiotropic effects of incretins; neurological effects, Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house, 2013, p113
- C. Gupta V; Pleiotropic effects of incretins; gastrointestinal and hepatobiliary effects, Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house, 2013, p117
- D. Gupta V; Pleiotropic effects of incretins; insulin sensitivity, Incretin based therapies: First Edition; Jaypee publishing house, 2013, p123
- E. Gupta V; Pleiotropic effects of incretins; obesity, Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house, 2013, p131
- F. Gupta V; choosing a DPP-4 inhibitor, Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house, 2013, p103